Drug discovery

Clinical Research Data Sharing Alliance (CRDSA) Hosts Virtual Summit

Retrieved on: 
Tuesday, February 20, 2024

PISCATAWAY, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) --  The Clinical Research Data Sharing Alliance (CRDSA) is convening leading experts from the scientific and regulatory communities for a virtual summit on the latest developments in patient-level data sharing and data reuse.

Key Points: 
  • PISCATAWAY, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) --  The Clinical Research Data Sharing Alliance (CRDSA) is convening leading experts from the scientific and regulatory communities for a virtual summit on the latest developments in patient-level data sharing and data reuse.
  • “ The Patient Data Revolution: From Promise to Realization ” will take place on February 29, 2024 from 10:00 a.m. to 1:00 p.m. EST.
  • “Answering key scientific questions about disease progression in untreated and undertreated patients, across diverse patient populations, is an increasingly complex proposition,” said Peter Mesenbrink, CRDSA board chair and executive director biostatistics, Novartis “It is important to make full and appropriate use of individual patients’ data, past and present, so that the necessary clinical research can be conducted to advance the science and serve patients.”
    The keynote address will be delivered by Mark McClellan, director of the Duke-Margolis Institute for Health Policy and former commissioner of the U.S. Food and Drug Administration.
  • This will be followed by sessions on the solutions being developed to facilitate and promote responsible secondary data use: a look at the regulatory horizon, a fireside chat on data protection governance, the debut of draft standards for secondary use and data contribution, and a closing discussion on how to support a data reuse ecosystem that best serves patients, accelerates drug discovery, and advances human health.

Fujifilm Celebrates Recent Recipients of Fujifilm Fellowships at Harvard Medical School

Retrieved on: 
Tuesday, February 20, 2024

CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Holdings America Corporation (Fujifilm), today announced the nine most recent Fujifilm Fellows at Harvard Medical School.

Key Points: 
  • CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Holdings America Corporation (Fujifilm), today announced the nine most recent Fujifilm Fellows at Harvard Medical School.
  • These PhD students from around the world are part of the Harvard Medical School Therapeutics Graduate Program working to advance therapeutics discovery, development, and applications to improve the treatment of disease.
  • Launched with six fellows in 2019, the Fujifilm Fellowship has now grown to reach 34 recipients to date, including six alumni.
  • “Fujifilm is proud to support Harvard Medical School as it helps to shape our world’s future scientists.

InveniAI Announces Collaboration with Ono Pharmaceutical for Target Discovery

Retrieved on: 
Monday, February 19, 2024

Ono will conduct validation studies to confirm the hypotheses for multiple therapeutic target candidates identified based on InveniAI’s drug discovery hypotheses.

Key Points: 
  • Ono will conduct validation studies to confirm the hypotheses for multiple therapeutic target candidates identified based on InveniAI’s drug discovery hypotheses.
  • Ono will retain exclusive rights to develop and commercialize drug candidates generated through this collaboration worldwide.
  • The collaboration with Ono marks a significant milestone in the pursuit of identifying and accelerating novel drug programs that address diseases with unmet medical needs.
  • "InveniAI is thrilled to partner with Ono, a company renowned for its commitment to innovation in drug discovery and development.

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 7, 2024

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its fourth quarter and full year 2023 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update.

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its fourth quarter and full year 2023 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update.
  • “Throughout 2023, our team has continued to advance our clinical and preclinical pipeline of differentiated cell transplant programs,” stated Brian M. Culley, Lineage CEO.
  • Long-term follow-up of patients from the Phase 1/2a clinical study of OpRegen:
    Positive clinical data presented at 2023 Eyecelerator , 23rd EU RETINA Congress , and 2023 ARVO Annual Meetings.
  • Initiated development activities for hypoimmune pluripotent cell line for neurology indications under collaboration with Eterna Therapeutics.

IPA’s subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology

Retrieved on: 
Thursday, March 7, 2024

The Company’s model uniquely combines the strengths of Large Language Models (LLMs) through an advanced stacking technique with BioStrand's patented HYFT Technology.

Key Points: 
  • The Company’s model uniquely combines the strengths of Large Language Models (LLMs) through an advanced stacking technique with BioStrand's patented HYFT Technology.
  • Central to the success of BioStrand's Foundation AI Model is its utilization of its patented HYFT technology, a sophisticated framework designed to identify and leverage universal fingerprint™ patterns across the biosphere.
  • The Advanced Foundation AI model employs a distinctive approach known as "LLM stacking" to intelligently combine different LLMs, with the HYFTs linked to specific features found in various LLMs.
  • Our presentation will focus on introducing our groundbreaking Universal Foundation AI Model for Multiscale Biological Data Integration.

Fierce Medtech Names Genesis Therapeutics a “Fierce 15” Company of 2023

Retrieved on: 
Wednesday, March 6, 2024

Genesis Therapeutics , a company pioneering generative and predictive artificial intelligence (AI) technologies to develop breakthrough therapeutics for underserved patient populations, today announced that Fierce Medtech has named it as one of 2023’s “Fierce 15” medtech companies.

Key Points: 
  • Genesis Therapeutics , a company pioneering generative and predictive artificial intelligence (AI) technologies to develop breakthrough therapeutics for underserved patient populations, today announced that Fierce Medtech has named it as one of 2023’s “Fierce 15” medtech companies.
  • "We are honored to receive this recognition from Fierce and be included among true innovators in AI and life sciences," said Evan Feinberg, Ph.D., co-founder and CEO of Genesis.
  • Being named a Fierce 15 company is testament that our team is yielding tangible results in developing AI technologies that generate transformative drugs for patients."
  • “These companies exemplify the ability of the life sciences industry to turn cutting-edge ideas into meaningful outcomes.”

India Artificial Intelligence in Drug Discovery Market Research Report 2024: A Lucrative Technology in Healthcare, Filling the Research and Development Gap in Drug Manufacturing - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 6, 2024

The "Artificial Intelligence in Drug Discovery Market in India, 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Artificial Intelligence in Drug Discovery Market in India, 2024" report has been added to ResearchAndMarkets.com's offering.
  • AI is poised to become a lucrative technology in healthcare, filling the research and development gap in drug manufacturing and enhancing targeted drug production.
  • In India's drug discovery field, AI utilizes advanced computational techniques to expedite various stages of drug development.
  • The stringent regulations and guidelines present a challenge, hindering the seamless integration of AI into India's drug discovery market.

Lantern To Participate in H.C Wainwright & Co.’s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference

Retrieved on: 
Tuesday, March 5, 2024

Lantern Pharma Inc. (NASDAQ: LTRN), a leader in AI-driven cancer drug discovery and development, announced that it will be presenting at a virtual conference being hosted by HCW.

Key Points: 
  • Lantern Pharma Inc. (NASDAQ: LTRN), a leader in AI-driven cancer drug discovery and development, announced that it will be presenting at a virtual conference being hosted by HCW.
  • The conference will be on Thursday, March 7th, and is a virtual event.
  • Lantern Pharma’s CEO, Mr. Panna Sharma, will be discussing and presenting via a fireside chat format at The 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference at approximately 2 pm Eastern / 11 am Pacific.
  • While addressing AI in drug discovery, Mr. Sharma will talk about how RADR®, Lantern’s proprietary AI platform, is transforming the cost, pace, and timeline of oncology drug development.

Velsera Announces Appointment of Jamie Littlejohns as New Chief Executive Officer

Retrieved on: 
Tuesday, March 5, 2024

Velsera, a pioneering entity in the field of computational biology with a focus on advancing precision medicine, is delighted to formally announce the appointment of Jamie Littlejohns as its Chief Executive Officer, with his tenure commencing on the 1st of March, 2024.

Key Points: 
  • Velsera, a pioneering entity in the field of computational biology with a focus on advancing precision medicine, is delighted to formally announce the appointment of Jamie Littlejohns as its Chief Executive Officer, with his tenure commencing on the 1st of March, 2024.
  • Jamie is set to succeed Hans Cobben, who has served as the interim CEO and will revert to his position as Chairman of the Board at Velsera.
  • In his own words, Jamie says, "I am thrilled to be joining the wonderful team at Velsera.
  • Furthermore, his prior experience with both Summa and Velsera enables him to hit the ground running, providing continuity whilst injecting his unique energy into Velsera.

ISG to Publish Reports on Vertical Industry Analytics

Retrieved on: 
Monday, March 4, 2024

The study results will be published in a series of three global ISG Provider Lens™ reports: “Retail Analytics Services — Specialist Providers” is scheduled to be released in July 2024, “Supply Chain Analytics Services — Specialist Providers” in August 2024, and “Life Sciences and Healthcare Services — Specialist Providers” in September 2024.

Key Points: 
  • The study results will be published in a series of three global ISG Provider Lens™ reports: “Retail Analytics Services — Specialist Providers” is scheduled to be released in July 2024, “Supply Chain Analytics Services — Specialist Providers” in August 2024, and “Life Sciences and Healthcare Services — Specialist Providers” in September 2024.
  • The three industries ISG is studying all are seeking to leverage AI-driven analytics to achieve critical business outcomes.
  • ISG analyst Manav Sachdeva will serve as the principal author of the reports.
  • Companies not listed as analytics services providers for any of the three industries can contact ISG and ask to be included in the study.